Beam Therapeutics Inc. (BEAM): Price and Financial Metrics

Beam Therapeutics Inc. (BEAM): $33.04

0.92 (-2.71%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add BEAM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#101 of 365

in industry

BEAM Price/Volume Stats

Current price $33.04 52-week high $49.50
Prev. close $33.96 52-week low $16.95
Day low $32.92 Volume 1,329,100
Day high $34.17 Avg. volume 1,380,013
50-day MA $32.23 Dividend yield N/A
200-day MA $27.90 Market Cap 2.70B

BEAM Stock Price Chart Interactive Chart >

BEAM POWR Grades

  • Momentum is the dimension where BEAM ranks best; there it ranks ahead of 27.6% of US stocks.
  • BEAM's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • BEAM's current lowest rank is in the Sentiment metric (where it is better than 1.88% of US stocks).

BEAM Stock Summary

  • BEAM's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 5,785.57 -- higher than 99.34% of US-listed equities with positive expected earnings growth.
  • Of note is the ratio of BEAM THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 7.35% of US stocks have a lower such ratio.
  • BEAM's price/sales ratio is 25.8; that's higher than the P/S ratio of 95.09% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BEAM THERAPEUTICS INC are TNGX, DNLI, ALT, NRIX, and RPTX.
  • Visit BEAM's SEC page to see the company's official filings. To visit the company's web site, go to www.beamtx.com.

BEAM Valuation Summary

  • BEAM's price/earnings ratio is -7.1; this is 124.36% lower than that of the median Healthcare stock.
  • Over the past 47 months, BEAM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for BEAM.

Stock Date P/S P/B P/E EV/EBIT
BEAM 2023-12-29 27.2 2.8 -7.1 -7.1
BEAM 2023-12-28 29.4 3.1 -7.6 -7.7
BEAM 2023-12-27 29.1 3.0 -7.6 -7.6
BEAM 2023-12-26 29.8 3.1 -7.7 -7.8
BEAM 2023-12-22 29.5 3.1 -7.7 -7.7
BEAM 2023-12-21 28.1 2.9 -7.3 -7.3

BEAM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BEAM has a Quality Grade of D, ranking ahead of 6.52% of graded US stocks.
  • BEAM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows BEAM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 1 -0.966
2021-03-31 0 1 -1.254
2020-12-31 0 1 -1.054
2020-09-30 0 1 -0.896
2019-12-31 0 1 -1.360

BEAM Price Target

For more insight on analysts targets of BEAM, see our BEAM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $123.57 Average Broker Recommendation 1.36 (Strong Buy)

Beam Therapeutics Inc. (BEAM) Company Bio


Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.


BEAM Latest News Stream


Event/Time News Detail
Loading, please wait...

BEAM Latest Social Stream


Loading social stream, please wait...

View Full BEAM Social Stream

Latest BEAM News From Around the Web

Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.

2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street

Wall Street is uber-bullish on these two Ark Invest holdings.

Yahoo | December 27, 2023

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […]

Yahoo | December 15, 2023

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 14, 2023

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry’s premier autologous cell therapy comp

Yahoo | December 14, 2023

Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?

Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Read More 'BEAM' Stories Here

BEAM Price Returns

1-mo -24.24%
3-mo 21.38%
6-mo 37.38%
1-year 9.59%
3-year -56.39%
5-year N/A
YTD 21.38%
2023 -30.40%
2022 -50.92%
2021 -2.39%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!